Our mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases.
Taking Big Steps
MorphoSys' mission
04/03/2020
MorphoSys Resolves a Capital Increase to Implement the Purchase of 3,629,...
03/03/2020
MorphoSys and Incyte Announce Antitrust Clearance of Global Collaboration...
02/03/2020
FDA Accepts MorphoSys' Biologics License Application (BLA) and Grants...
04/02/2020
MorphoSys Initiates Expanded Access Program for Tafasitamab in the U.S.
13/01/2020
MorphoSys and Incyte Sign Global Collaboration and License Agreement for...
13/01/2020
MorphoSys AG: Ad hoc: MorphoSys and Incyte Sign Global Collaboration and...
30/12/2019
MorphoSys Announces Submission of Biologics License Application for...
27/12/2019
First Patient Dosed in Phase 1 Clinical Study of Tafasitamab in Firstline...
